IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 97 filers reported holding IMMUNOVANT INC in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47,867,570 | +486.9% | 1,246,876 | +190.0% | 0.01% | +900.0% |
Q2 2023 | $8,156,132 | -59.8% | 429,949 | -67.1% | 0.00% | -75.0% |
Q1 2023 | $20,286,708 | -2.1% | 1,307,976 | +12.0% | 0.00% | -20.0% |
Q4 2022 | $20,723,516 | +1735.6% | 1,167,522 | +477.0% | 0.01% | – |
Q3 2022 | $1,129,000 | -14.6% | 202,333 | -40.3% | 0.00% | – |
Q2 2022 | $1,322,000 | -48.6% | 338,905 | -27.4% | 0.00% | – |
Q1 2022 | $2,570,000 | -57.1% | 466,591 | -33.6% | 0.00% | -100.0% |
Q4 2021 | $5,991,000 | -39.3% | 703,161 | -38.1% | 0.00% | 0.0% |
Q3 2021 | $9,874,000 | -24.9% | 1,136,243 | -8.6% | 0.00% | -50.0% |
Q2 2021 | $13,146,000 | +5.0% | 1,243,712 | +59.4% | 0.00% | -33.3% |
Q1 2021 | $12,516,000 | -64.8% | 780,341 | +1.5% | 0.00% | -66.7% |
Q4 2020 | $35,521,000 | +44.0% | 769,034 | +9.7% | 0.01% | +28.6% |
Q3 2020 | $24,671,000 | +374.3% | 701,075 | +228.1% | 0.01% | +250.0% |
Q2 2020 | $5,202,000 | +1784.8% | 213,652 | +1103.3% | 0.00% | – |
Q1 2020 | $276,000 | – | 17,756 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |